CSE:BIOV - Post Discussion
Post by
johnfever21 on Mar 21, 2022 8:56am
Biov to develop omni variant booster
Biovaxys intends to develop BVX-1021 as a stand-alone booster targeting anyone who has been immunized with a World Health Organization recognized COVID-19 vaccine or convalesced from a COVID-19 infection. To date, approximately 389 million people worldwide have recovered from COVID-19 (Worldometer; March 11, 2022), and 57 per cent of the global population (Our World in Data; March, 2022), or 4.4 billion people, have received a full course of SARS-CoV-2 vaccine.
Millipore is a subsidiary of Merck KGaA, one of the largest pharmaceutical companies in the world, with a market capitalization of $81-billion (U.S.)
Kenneth Kovan, president and chief operating officer of Biovaxys, stated: "The COVID-19 market is shifting to vaccines that will not only protect against emerging variants of SARS-CoV-2, but also for any related coronaviruses that likely may arise in the future. BVX-1021 demonstrates that we can leverage our technology platform to create novel hapten-viral antigen vaccines to target additional markets."
Be the first to comment on this post